BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Presentation Highlights Clinical Potential of Navidea Biopharmaceuticals (NEOP)’ ß-Amyloid Imaging Biomarker AZD4694


5/29/2012 10:14:39 AM

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced Phase 1 and Phase 2 clinical trials data from its radiopharmaceutical candidate, AZD4694 for the detection of amyloid in patients with Alzheimer's disease, were presented at the recent 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy meeting. The bi-annual conference focuses on pharmacological therapy in Alzheimer’s disease (AD) and is organized by the Karolinska Institute, Sweden, University of Geneva, Switzerland, and Southern Illinois University, U.S. The three-day meeting featured world leaders in Alzheimer’s disease innovation discussing new trial designs, animal models, and neuroimaging including PET and diagnostic recommendations. In December 2011 Navidea announced that it had in-licensed the worldwide rights for AZD4694 from AstraZeneca.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES